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It was a pleasant surprise for those of us in the Out-
comes Research community to see a health econo-
mist lead the Food and Drug Administration (FDA)
albeit for a very short time. In this issue, Value in
Health presents its transcript of a speech Dr Mark
McClellan gave at ISPOR last year [1].
The speech was part of a plenary session on real
world databases in health care. Dr McClellan has
been a pioneer in the use of such databases. Several
of his earlier publications related to his using them
in innovative ways to examine the costs and effec-
tiveness of various technologies [2–5].
Given his background, was Dr McClellan intend-
ing to incorporate cost-effectiveness into the FDA
approval process? He explicitly addressed this ques-
tion, and his answer was “no.” Instead, he brought
to the FDA a vision about the opportunity of infor-
mation technology to improve the performance of
the agency and reduce health-care costs.
Dr McClellan is aware of both the high cost of
medications and the high cost of drug development.
Cost pressures in both arenas drive the search for
new efﬁciencies, and Dr McClellan’s background
has led him to identify several important
opportunities.
He ﬁrst addressed the role of the FDA in drug
development. Dr McClellan developed initiatives to
prevent repeat cycles in FDA reviews, share best
practices within the FDA, and provide better public
guidance. Hopefully these initiatives will lead to
more efﬁcient investment in research.
Dr McClellan also developed initiatives to
expand the use of information technologies in drug
prescribing. The FDA proposed a new rule to
require a universal bar coding system for prescrip-
tion medications and blood products. This offers
the potential to prevent a large number of costly
adverse events.
Third, he initiated pilot programs expanding the
use of real world databases in post-market surveil-
lance. One project involved several leading aca-
demic medical centers sending adverse event data to
the FDA in an automated fashion. Another project
has involved systematic collection of data on med-
ical devices in real time, permitting the FDA to
quickly identify and address issues of public safety.
So it should be no surprise that the President of
the United States has recently spoken on the need to
computerize American health care. George W. Bush
said “. . . Medicine ought to be using modern tech-
nologies in order to better share information, in
order to reduce medical errors, in order to reduce
costs to our health-care system by billions of dollars
[6].”
These statements by the President are completely
in line with the focus and vision of Dr McClellan.
While some health economists focus on health-care
rationing, Dr McClellan has placed his focus
instead on facilitating innovation, adopting new
technologies, and increasing efﬁciency. It is a great
way to promote value in health.
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